About BioLattice
BioLattice is a company based in Philadelphia (United States) founded in 2017 by Amelia Zellander and Linda Alunkal. BioLattice has raised $575 thousand across 2 funding rounds from investors including National Science Foundation. BioLattice offers products and services including Engineered Cornea. BioLattice operates in a competitive market with competitors including CorneaGen, Cellusion, EyeGate, Avedro and CorNeat Vision, among others.
- Headquarter Philadelphia, United States
- Founders Amelia Zellander, Linda Alunkal
- SectorsHealthcare
- Email••••••••
- Website biolatticetech.com
- Social LinkedIn
- Legal Name Biolattice Ophthalmics, Inc.
- Total Equity Funding$575K (USD)
in 2 rounds
- Latest Funding Round$575K (USD), Seed
Mar 2026
- Investors
Products & Services of BioLattice
BioLattice offers a comprehensive portfolio of products and services, including Engineered Cornea.
Alternative to donor tissue for cornea transplants to restore vision.
Funding Insights of BioLattice
BioLattice has successfully raised a total of $575K across 2 strategic funding rounds. The most recent funding activity was a Seed round of $575 thousand completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $575,000
- Total Rounds 2
- Last Round Seed — $575,000
- First Round $274,416
(Dec 2023)
- Investors Count 1
All 2 funding rounds of BioLattice with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $575,000 | Seed | – | – | – |
| Dec 2023 | $274,416 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in BioLattice
BioLattice has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for BioLattice
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioLattice
2 people are tracked at BioLattice (2 in leadership).
| Name | Role | Group |
|---|---|---|
Amelia Zellander | Co-Founder & CEO | Leadership |
Linda Alunkal | Co-Founder | Leadership |
Complete people profiles for BioLattice
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioLattice
3 dated milestones of BioLattice across 9 years, from founding to its latest funding, stage changes and deals.
- Founded BioLattice is founded.
- Funding First funding round of $274K.
- Funding Latest funding round, Seed, of $575K.
Competitors of BioLattice
BioLattice operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as CorneaGen, Cellusion, EyeGate, Avedro and CorNeat Vision, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| corneagen.com | 2017 | Seattle, United States | $42M | 205 | Therapeutic devices for corneal transplants are developed by CorneaGen. | |
| cellusion.jp | 2015 | Minato, Japan | $29.71M | – | iPS cell-based technology for corneal endothelium regeneration is developed. | |
| eyegatepharma.com | 1998 | Waltham, United States | $44.47M | 12 | Therapeutics and drug delivery systems for eye diseases are developed. | |
| avedro.com | 2007 | Waltham, United States | $210.76M | 113 | Corneal collagen cross-linking technology is developed for ophthalmic applications. | |
| corneat.com | 2015 | – | $4M | – | Nanotechnology-based artificial corneal implants are developed for ophthalmic use. | |
| eye-yon.com | 2011 | Ness Ziona, Israel | $35.1M | – | Ophthalmic devices for corneal edema treatment are developed. | |
| nueyne.com | 2017 | Seoul, South Korea | – | – | Medical devices using electrical stimulation for health conditions are developed. | |
| recornea.com | 2019 | Udine, Italy | $161,997 | – | Provider of corneal implants devices for the treatment of eye diseases |
Detailed competitors of BioLattice
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to BioLattice
10 companies that operate in the same segment as BioLattice (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about BioLattice
BioLattice was founded in 2017 and raised its 1st funding round 6 years after it was founded.
BioLattice is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
Amelia Zellander is the current CEO of BioLattice. They have also founded this company.
BioLattice is a funded company, having raised a total of $575K across 2 funding rounds to date. The company's 1st funding round was a Grant of $274.42K, raised on Dec 2023.
BioLattice was founded in 2017 in Philadelphia, United States, within the biotechnology sector. Focus is placed on engineering solutions for tissue repair, including an artificial cornea designed as an alternative to human donor corneas. Operations center on research and development of regenerative technologies to address unmet needs in ophthalmology and tissue restoration. The company is led by co-founders Amelia Zellander as CEO and Linda Alunkal.
BioLattice offers Engineered Cornea.
BioLattice has 1 investor. Key investors include National Science Foundation.
BioLattice operates through Biolattice Ophthalmics, Inc..